Valeant Buyout Brings Marketing Clout To Sprout And Addyi

Canada’s M&A specialist agrees to pay $1bn for the female sexual desire drug just two days after its FDA approval, taking the North Carolina firm in-house as a subsidiary focused on global registration of Addyi.